Time Is Now For Shaping CMS Drug Affordability, Innovation Policies – Slavitt
This article was originally published in The Pink Sheet Daily
Executive Summary
Acting Administrator Andy Slavitt explains CMS is in information-gathering mode as it considers ways of addressing accelerating drug costs in Medicare and Medicaid.
You may also be interested in...
Paying For Cures Requires Bigger Budgets, Not Lower Drug Prices – Execs
Payors need to adopt a longer-term focus on coverage policies for prescription drugs and biologics that recognizes the benefits of covering high-priced, but often curative, treatments like those for hepatitis C, panelists argue at AEI-sponsored event.
CMS Wants To Facilitate Value-Based Discounts For HCV Drugs In Medicaid
CMS requests information from hepatitis C manufacturers on how value-based purchasing arrangements might work in Medicaid. Agency also urges state Medicaid directors to relax overly strict coverage requirements for the drugs.
HHS Raises Profile In Drug Costs Discussion
On Nov. 20, HHS will host a day-long forum on pharmaceuticals, including a look at high-cost specialty drugs and innovative purchasing strategies.